TY - JOUR
T1 - Gene expression in Leishmania is regulated predominantly by gene dosage
AU - Iantorno, Stefano A.
AU - Durrant, Caroline
AU - Khan, Asis
AU - Sanders, Mandy J.
AU - Beverley, Stephen M.
AU - Warren, Wesley C.
AU - Berriman, Matthew
AU - Sacks, David L.
AU - Cotton, James A.
AU - Grigg, Michael E.
N1 - Funding Information:
We acknowledge funding from the Wellcome Trust via their core support for the Wellcome Trust Sanger Institute (grant 206194).
Funding Information:
This study was financially supported in part by the Intramural Research Program of the NIH and NIAID, by NIH grant AI29646 to S.M.B., and by NIH-NHGRI grant 5U54HG00307907 to Richard K. Wilson, Director of the Genome Institute at Washington University. M.E.G. is a scholar of the Canadian Institute for Advanced Research Integrated Microbial Biodiversity Program.
Funding Information:
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USAa; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdomb; Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USAc; McDonnell Genome Institute, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USAd
Publisher Copyright:
© 2017, American Society for Microbiology. All rights reserved.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Leishmania tropica, a unicellular eukaryotic parasite present in North and East Africa, the Middle East, and the Indian subcontinent, has been linked to large outbreaks of cutaneous leishmaniasis in displaced populations in Iraq, Jordan, and Syria. Here, we report the genome sequence of this pathogen and 7,863 identified protein-coding genes, and we show that the majority of clinical isolates possess high levels of allelic diversity, genetic admixture, heterozygosity, and extensive aneuploidy. By utilizing paired genome-wide high-throughput DNA sequencing (DNA-seq) with RNA-seq, we found that gene dosage, at the level of individual genes or chromosomal “somy” (a general term covering disomy, trisomy, tetrasomy, etc.), accounted for greater than 85% of total gene expression variation in genes with a 2-fold or greater change in expression. High gene copy number variation (CNV) among membrane-bound transporters, a class of proteins previously implicated in drug resistance, was found for the most highly differentially expressed genes. Our results suggest that gene dosage is an adaptive trait that confers phenotypic plasticity among natural Leishmania populations by rapid down- or upregulation of transporter proteins to limit the effects of environmental stresses, such as drug selection. IMPORTANCE Leishmania is a genus of unicellular eukaryotic parasites that is responsible for a spectrum of human diseases that range from cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL) to life-threatening visceral leishmaniasis (VL). Developmental and strain-specific gene expression is largely thought to be due to mRNA message stability or posttranscriptional regulatory networks for this species, whose genome is organized into polycistronic gene clusters in the absence of promoter-mediated regulation of transcription initiation of nuclear genes. Genetic hybridization has been demonstrated to yield dramatic structural genomic variation, but whether such changes in gene dosage impact gene expression has not been formally investigated. Here we show that the predominant mechanism determining transcript abundance differences (>85%) in Leishmania tropica is that of gene dosage at the level of individual genes or chromosomal somy.
AB - Leishmania tropica, a unicellular eukaryotic parasite present in North and East Africa, the Middle East, and the Indian subcontinent, has been linked to large outbreaks of cutaneous leishmaniasis in displaced populations in Iraq, Jordan, and Syria. Here, we report the genome sequence of this pathogen and 7,863 identified protein-coding genes, and we show that the majority of clinical isolates possess high levels of allelic diversity, genetic admixture, heterozygosity, and extensive aneuploidy. By utilizing paired genome-wide high-throughput DNA sequencing (DNA-seq) with RNA-seq, we found that gene dosage, at the level of individual genes or chromosomal “somy” (a general term covering disomy, trisomy, tetrasomy, etc.), accounted for greater than 85% of total gene expression variation in genes with a 2-fold or greater change in expression. High gene copy number variation (CNV) among membrane-bound transporters, a class of proteins previously implicated in drug resistance, was found for the most highly differentially expressed genes. Our results suggest that gene dosage is an adaptive trait that confers phenotypic plasticity among natural Leishmania populations by rapid down- or upregulation of transporter proteins to limit the effects of environmental stresses, such as drug selection. IMPORTANCE Leishmania is a genus of unicellular eukaryotic parasites that is responsible for a spectrum of human diseases that range from cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL) to life-threatening visceral leishmaniasis (VL). Developmental and strain-specific gene expression is largely thought to be due to mRNA message stability or posttranscriptional regulatory networks for this species, whose genome is organized into polycistronic gene clusters in the absence of promoter-mediated regulation of transcription initiation of nuclear genes. Genetic hybridization has been demonstrated to yield dramatic structural genomic variation, but whether such changes in gene dosage impact gene expression has not been formally investigated. Here we show that the predominant mechanism determining transcript abundance differences (>85%) in Leishmania tropica is that of gene dosage at the level of individual genes or chromosomal somy.
KW - CNV
KW - Gene dosage
KW - Gene expression
KW - Leishmania
KW - RNA-seq
UR - http://www.scopus.com/inward/record.url?scp=85033709509&partnerID=8YFLogxK
U2 - 10.1128/mBio.01393-17
DO - 10.1128/mBio.01393-17
M3 - Article
C2 - 28900023
AN - SCOPUS:85033709509
SN - 2161-2129
VL - 8
JO - mBio
JF - mBio
IS - 5
M1 - e01393-17
ER -